Gabather AB (GABA) AI Stock Analysis

• Market Cap: €7.79M
• Dividend Yield: N/A
• Average Volume (3M): 559.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: N/A
• EPS Growth: 71.92%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 236,204,880
• 10 Day Avg. Volume: 582,336
• 30 Day Avg. Volume: 559,788
• PEG Ratio: 0.02
• Price to Book (P/B): -1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Gabather AB's stock is significantly hampered by its financial distress, with negative equity and no revenue generation posing severe risks. While the technical indicators suggest a bearish trend, the lack of income potential and negative valuation metrics further drag down the overall score. The absence of earnings call and corporate events data means these factors do not influence the score.

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.

How the Company Makes Money

Gabather AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's business model involves advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval. Success in these trials can lead to partnerships with larger pharmaceutical companies, licensing agreements, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from partnerships, as well as potential sales revenue from successful drug commercialization. Gabather may also engage in research collaborations that contribute to its earnings.

Gabather AB Financial Statement Overview

Summary

Gabather AB faces significant financial challenges, marked by an absence of revenue, persistent losses, and negative cash flow. The company's financial position is weakened by negative equity and declining cash reserves. Despite no debt, the lack of revenue and cash generation is concerning for its financial future.

Income Statement

Gabather AB has consistently reported zero revenue, indicating challenges in commercializing its products. The company continues to incur significant net losses, with a slightly reduced EBIT loss in the most recent year compared to the previous year. The absence of revenue growth is a major concern.

Balance Sheet

The balance sheet shows negative stockholders' equity, indicating financial distress and potential solvency issues. While the company has no debt, its liabilities exceed its assets, and the deteriorating equity position raises concerns about financial stability.

Cash Flow

Operating cash flow remains negative, reflecting ongoing cash burn without revenue generation. Free cash flow is also negative, though there was a reduction in cash outflow due to financing activities. The cash position has declined sharply over recent years, impacting liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-4.12M	0.00	37.00K	-8.55M	-16.99M	-14.66M
Net Income	-4.46M	-7.75M	-9.44M	-8.54M	-17.00M	-14.95M
Balance Sheet
Total Assets	3.50M	1.83M	7.36M	6.75M	15.39M	32.16M
Cash, Cash Equivalents and Short-Term Investments	3.00M	878.00K	1.11M	6.27M	14.85M	30.92M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.48M	6.01M	6.88M	3.31M	4.43M	3.31M
Stockholders Equity	-983.00K	-4.17M	486.00K	3.44M	10.96M	27.91M
Cash Flow
Free Cash Flow	-5.16M	-3.33M	-11.64M	-9.60M	-16.12M	-13.98M
Operating Cash Flow	-5.16M	-3.33M	-11.64M	-9.60M	-16.12M	-13.69M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	-289.00K
Financing Cash Flow	7.18M	3.09M	6.49M	1.02M	46.00K	0.00

Gabather AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.20 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GABA.

Gabather AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALZCUR	47 Neutral	€301.08M	―	-161.07%	―	―	22.73%
NANEXA	44 Neutral	€326.37M	―	-34.87%	―	-38.56%	69.37%
KLAR	41 Neutral	€129.88M	―	-3899.10%	―	1523.75%	20.82%
GABA	28 Underperform	€7.79M	―	―	―	―	71.92%